论文部分内容阅读
为了探讨利妥昔单克隆抗体联合氟达拉滨及环磷酰胺(FCR方案)治疗慢性淋巴细胞白血病(CLL)的疗效,采用FCR方案(2-6个疗程)治疗5例CLL患者,其中2例初治、3例复治。FCR方案包括氟达拉滨25mg/m2第2-4天静脉滴注,环磷酰胺250mg/m2第2-4天静脉滴注,利妥昔单克隆抗体375mg/m2第1天静脉滴注,每28天1个疗程。采用多参数流式细胞术检测微小残留病灶(MRD)。结果表明:3例达完全缓解,2例部分缓解;5例中2例MRD检测为阴性。FCR方案的毒副作用主要表现为骨髓抑制和胃肠道反应。结论:FCR方案对CLL的治疗有确切疗效,值得进一步推广使用。
To investigate the efficacy of rituximab combined with fludarabine and cyclophosphamide (FCR regimen) in the treatment of chronic lymphocytic leukemia (CLL), 5 CLL patients were treated with FCR regimen (2-6 cycles), of which 2 Example of early treatment, 3 cases of retreatment. FCR regimen included intravenous infusion of fludarabine 25 mg / m2 on day 2-4, intravenous infusion of cyclophosphamide 250 mg / m2 on day 2-4, intravenous infusion of rituximab 375 mg / m2 on day 1, Every 28 days a course of treatment. Multi-parameter flow cytometry was used to detect minimal residual disease (MRD). The results showed that: 3 patients achieved complete remission, 2 patients partially relieved; 5 patients 2 MRD test was negative. The toxic side effects of the FCR regimen are mainly myelosuppression and gastrointestinal reactions. Conclusion: The FCR regimen has definite curative effect on the treatment of CLL and is worth further promotion.